December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Effect of Latanoprost Therapy on Contrast Sensitivity in Glaucoma Patients
Author Affiliations & Notes
  • DW Evans
    Optometry Univ of Alabama - Birmingham Birmingham AL
  • J Bartlett
    Optometry Univ of Alabama - Birmingham Birmingham AL
  • B Houde
    Optometry Univ of Alabama - Birmingham Birmingham AL
  • T Than
    Optometry Univ of Alabama - Birmingham Birmingham AL
  • Footnotes
    Commercial Relationships    D.W. Evans, VectorVision I; J. Bartlett, None; B. Houde, None; T. Than, None. Grant Identification: Unresticted Grant From Pharmacia
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2129. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      DW Evans, J Bartlett, B Houde, T Than; Effect of Latanoprost Therapy on Contrast Sensitivity in Glaucoma Patients . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2129.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Previous studies have demonstrated that visual function as measured by contrast sensitivity (CS) improves in primary open-angle glaucoma (POAG) patients following ocular hypotensive therapy. Some data suggests that certain treatments may provide improved visual function despite no or only a small change in IOP. The purpose of this study was to prospectively compare the effects of latanoprost and timolol maleate in Gelrite on CS. Methods: Twenty POAG patients on a monotherapy treatment regimen of topical beta blockade and with clinically stable IOP were recruited for this single-masked, randomized, crossover study. Subjects were randomized to begin treatment with latanoprost 0.005% once daily in the evening or timolol maleate 0.5% in Gelrite once daily in the morning. At the end of a 3-month treatment period, each subject was crossed-over to receive the alternative treatment for three months. Blood pressure, heart rate, IOP, and CS (CSV-1000E, VectorVision) were assessed at baseline and after 4, 12, 16, and 24 weeks of treatment. CS was evaluated at four spatial frequencies, 3, 6, 12, and 18 cycles/degree. Visual field sensitivity was evaluated using the Humphrey 24-2 Fastpac program at baseline and after 12 and 24 weeks of treatment. Results: Subjects who were treated for three months with latanoprost, after being switched from timolol, experienced an improvement in CS at 3 cpd (p=0.03). Conversely, subjects who were treated for three months with timolol, after being switched from latanaprost, demonstrated a significant loss in CS at 3 cpd (p=0.04) and at 18 cpd (p=0.03). Neither group demonstrated a change in IOP or visual field sensitivity. Conclusion: Compared with timolol maleate in Gelrite, latanoprost appears to significantly improve central visual function as measured by contrast sensitivity.

Keywords: 368 contrast sensitivity • 514 pharmacology • 444 intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×